{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:25:52Z","timestamp":1789763152902,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To assess the current state of statin use, factors associated with non-use, and estimate the burden of potentially preventable atherosclerotic cardiovascular diseases (ASCVD) events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Using nationally representative data from the 2017 to 2020 National Health and Nutrition Examination Survey, statin use was assessed in primary prevention groups: high ASCVD risk \u2265 20%, LDL-cholesterol (LDL-C) \u2265 190\u2005mg\/dL, diabetes aged 40\u201375 years, intermediate ASCVD risk (7.5 to &amp;lt;20%) with \u22651 ASCVD risk enhancer and secondary prevention group: established ASCVD. Atherosclerotic cardiovascular disease risk was estimated using pooled cohort equations. We estimated 70 million eligible individuals (2.3 million with LDL-C \u2265 190\u2005mg\/dL; 9.4 million with ASCVD \u2265 20%; 15 million with diabetes and age 40\u201375years; 20 million with intermediate ASCVD risk and \u22651 risk enhancers; and 24.6 million with established ASCVD), about 30 million were on statin therapy. The proportion of individuals not on statin therapy was highest in the isolated LDL-C \u2265 190\u2005mg\/dL group (92.8%) and those with intermediate ASCVD risk plus enhancers (74.6%) followed by 59.4% with high ASCVD risk, 54.8% with diabetes, and 41.5% of those with established ASCVD groups. Increasing age and those with health insurance were more likely to be on statin therapy in both the primary and secondary prevention categories. Individuals without a routine place of care were less likely to be on statin therapy. A total of 385 000 (high-intensity statin) and 647 000 (moderate-intensity statin) ASCVD events could be prevented if all statin-eligible individuals were treated (and adherent) for primary prevention over a 10-year period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Statin use for primary and secondary prevention of ASCVD remains suboptimal. Bridging the therapeutic gap can prevent \u223c1 million ASCVD events over the subsequent 10 years for the primary prevention group. Social determinants of health such as access to care and healthcare coverage were associated with less statin treatment. Novel interventions to improve statin prescription and adherence are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwac103","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:25:01Z","timestamp":1654190701000},"page":"1830-1838","source":"Crossref","is-referenced-by-count":28,"title":["Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017\u20132020"],"prefix":"10.1093","volume":"29","author":[{"given":"Muchi Ditah","family":"Chobufo","sequence":"first","affiliation":[{"name":"Division of Cardiology, West Virginia University , Morgantown, WV 26506 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R","family":"Regner","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Virginia University , Morgantown, WV 26506 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4043-1871","authenticated-orcid":false,"given":"Irfan","family":"Zeb","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Virginia University , Morgantown, WV 26506 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan L","family":"Lacoste","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, WVU Medicine , Morgantown, WV , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-6954","authenticated-orcid":false,"given":"Salim S","family":"Virani","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine , Houston, TX , USA"},{"name":"Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-3757","authenticated-orcid":false,"given":"Sudarshan","family":"Balla","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Virginia University , Morgantown, WV 26506 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2022102020072791600_zwac103-B1","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102020072791600_zwac103-B2","doi-asserted-by":"crossref","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022102020072791600_zwac103-B3","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102020072791600_zwac103-B4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10557-020-07057-y","article-title":"Statin prescription rates, adherence, and associated clinical outcomes among women with PAD and ICVD","volume":"34","author":"Mahtta","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022102020072791600_zwac103-B5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","article-title":"Gender disparities in evidence-based statin therapy in patients with cardiovascular disease","volume":"115","author":"Virani","year":"2015","journal-title":"Am J Cardiol"},{"key":"2022102020072791600_zwac103-B6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ahj.2017.08.005","article-title":"Lipid management in contemporary community practice: results from the Provider Assessment of Lipid Management (PALM) Registry","volume":"193","author":"Navar","year":"2017","journal-title":"Am Heart J"},{"key":"2022102020072791600_zwac103-B7"},{"key":"2022102020072791600_zwac103-B8"},{"key":"2022102020072791600_zwac103-B9","article-title":"How the census bureau measures poverty","author":"U.S. Census Bureau"},{"key":"2022102020072791600_zwac103-B10"},{"key":"2022102020072791600_zwac103-B11","first-page":"e285","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"2019","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102020072791600_zwac103-B12","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)"},{"key":"2022102020072791600_zwac103-B13","article-title":"National health and nutrition examination survey","author":"Johnson"},{"key":"2022102020072791600_zwac103-B14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","article-title":"Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat","volume":"4","author":"Mortensen","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102020072791600_zwac103-B15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Investigators TSP by AR in CL (SPARCL)","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102020072791600_zwac103-B16","first-page":"820","article-title":"WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE)","volume":"83","author":"Mendis","year":"2005","journal-title":"Bull World Health Organ"},{"key":"2022102020072791600_zwac103-B17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"2022102020072791600_zwac103-B18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022102020072791600_zwac103-B19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/2047487312444995","article-title":"Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study","volume":"20","author":"Vedin","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"2022102020072791600_zwac103-B20"},{"key":"2022102020072791600_zwac103-B21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7326\/0003-4819-156-12-201206190-00420","article-title":"Lipitor goes generic: business as usual or more big business?","volume":"156","author":"Gill","year":"2012","journal-title":"Ann Intern Med"},{"key":"2022102020072791600_zwac103-B22","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2022102020072791600_zwac103-B23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s11606-018-4497-4","article-title":"Estimated impact of US preventive services task force recommendations on use and cost of statins for cardiovascular disease prevention","volume":"33","author":"Ngo-Metzger","year":"2018","journal-title":"J Gen Intern Med"},{"key":"2022102020072791600_zwac103-B24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/HCO.0000000000000893","article-title":"Impact of social determinants of health on cardiovascular disease prevention","volume":"36","author":"Mannoh","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2022102020072791600_zwac103-B25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/hec.4155","article-title":"The effects of public health insurance on health behaviors: evidence from the fifth year of Medicaid expansion","volume":"29","author":"Soni","year":"2020","journal-title":"Health Econ"},{"key":"2022102020072791600_zwac103-B26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pam.21972","article-title":"The impact of health insurance on preventive care and health behaviors: evidence from the first two years of the ACA Medicaid expansions","volume":"36","author":"Simon","year":"2017","journal-title":"J Policy Anal Manage"},{"key":"2022102020072791600_zwac103-B27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s11606-018-4537-0","article-title":"Third year of survey data shows continuing benefits of Medicaid expansions for low-income childless adults in the U.S","volume":"33","author":"Cawley","year":"2018","journal-title":"J Gen Intern Med"},{"key":"2022102020072791600_zwac103-B28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"2022102020072791600_zwac103-B29","doi-asserted-by":"crossref","first-page":"e004652","DOI":"10.1161\/CIRCOUTCOMES.118.004652","article-title":"Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol \u2265190\u2005mg\/dL: insights from the national cardiovascular data registry-practice innovation and clinical excellence registry","volume":"11","author":"Virani","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022102020072791600_zwac103-B30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.amjcard.2018.05.008","article-title":"Frequency of statin use in patients with low-density lipoprotein cholesterol \u2265190\u2005mg\/dl from the veterans affairs health system","volume":"122","author":"Rodriguez","year":"2018","journal-title":"Am J Cardiol"},{"key":"2022102020072791600_zwac103-B31","first-page":"40","article-title":"Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing","volume":"6","author":"Adusumalli","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102020072791600_zwac103-B32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jacc.2021.06.048","article-title":"Technology-assisted self-selection of candidates for nonprescription statin therapy","volume":"78","author":"Steven","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102020072791600_zwac103-B33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ahj.2013.02.011","article-title":"Gender and racial disparities in adherence to statin therapy: a meta-analysis","volume":"165","author":"Lewey","year":"2013","journal-title":"Am Heart J"},{"key":"2022102020072791600_zwac103-B34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jamacardio.2021.0683","article-title":"Sex-related disparities in cardiovascular health care among patients with premature atherosclerotic cardiovascular disease","volume":"6","author":"Lee","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102020072791600_zwac103-B35","doi-asserted-by":"crossref","first-page":"e005562","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022102020072791600_zwac103-B36","article-title":"An Investigation of Nonresponse Bias and Survey Location Variability in the 2017-2018 National Health and Nutrition Examination Survey","author":"Fakhouri"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwac103\/43966087\/zwac103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/14\/1830\/46582754\/zwac103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/14\/1830\/46582754\/zwac103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T20:08:28Z","timestamp":1666296508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/29\/14\/1830\/6599013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":36,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2022,10,20]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwac103","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,6,2]]}}}